Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
Kerr RS., Love S., Segelov E., Johnstone E., Falcon B., Hewett P., Weaver A., Church D., Scudder C., Pearson S., Julier P., Pezzella F., Tomlinson I., Domingo E., Kerr DJ.